Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Quest Diagnostics, Lee Health team up on laboratory services in Florida » 06:46
09/15/22
09/15
06:46
09/15/22
06:46
DGX

Quest Diagnostics

$124.06 /

-2.08 (-1.65%)

Quest Diagnostics and Lee…

Quest Diagnostics and Lee Health, Southwest Florida's primary community-owned health system, are teaming up to enhance diagnostic services to patients and their doctors. Under the agreement Quest will provide supply chain expertise in laboratory equipment, supplies and procurement processes for five hospitals owned by Lee Health and selected outpatient centers. Quest will also continue to perform reference testing for Lee Health.

ShowHide Related Items >><<
DGX Quest Diagnostics
$124.06 /

-2.08 (-1.65%)

DGX Quest Diagnostics
$124.06 /

-2.08 (-1.65%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
DGX Quest Diagnostics
$124.06 /

-2.08 (-1.65%)

DGX Quest Diagnostics
$124.06 /

-2.08 (-1.65%)

Hot Stocks
Quest Diagnostics announces strategic agreement with Hound Labs » 08:18
09/13/22
09/13
08:18
09/13/22
08:18
DGX

Quest Diagnostics

$131.67 /

+1.67 (+1.28%)

Hound Labs announces…

Hound Labs announces their agreement with Quest Diagnostics. The agreement establishes Quest as the exclusive provider of laboratory services for confirmatory testing of positive breath sample results generated by the HOUND CANNABIS BREATHALYZER, used by employers on location as an objective measure to detect and deter cannabis use during the workday. The HOUND CANNABIS BREATHALYZER identifies cannabis used within hours of testing and automatically processes results on-location within minutes. Negative test results indicate an employee is not likely to have used cannabis immediately preceding or during the workday. Under the terms, Quest Diagnostics will use a novel mass spectrometry technique it recently developed and validated at its Lenexa, KS, laboratory to confirm positive results from the Hound solution. "As a leader in laboratory diagnostics and workforce drug testing, Quest is ideally positioned to confirm positive results from the HOUND CANNABIS BREATHALYZER when our customers' best practices require a confirmatory lab test," said Nina French, President of Employer and Law Enforcement Solutions, with Hound Labs. "Cannabis legalization has prompted some employers to reconsider their workplace cannabis testing policies. They now need to know when an employee used cannabis to align test results more effectively with program objectives. We are excited Quest is working with us on our mission to help employers balance SAFETY+FAIRNESS."

ShowHide Related Items >><<
DGX Quest Diagnostics
$131.67 /

+1.67 (+1.28%)

DGX Quest Diagnostics
$131.67 /

+1.67 (+1.28%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
DGX Quest Diagnostics
$131.67 /

+1.67 (+1.28%)

DGX Quest Diagnostics
$131.67 /

+1.67 (+1.28%)

Conference/Events
Wells Fargo to hold a conference » 04:55
09/09/22
09/09
04:55
09/09/22
04:55
ABBV

AbbVie

$140.52 /

+1.48 (+1.06%)

, AVEO

Aveo Pharmaceuticals

$8.59 /

+0.28 (+3.37%)

, BNFT

Benefitfocus

$6.92 /

-0.13 (-1.84%)

, DGX

Quest Diagnostics

$130.17 /

+2.86 (+2.25%)

, FATE

Fate Therapeutics

$28.25 /

+0.935 (+3.42%)

, INSP

Inspire Medical

$197.41 /

+8.2 (+4.33%)

, LEGN

Legend Biotech

$43.61 /

-0.25 (-0.57%)

, GILD

Gilead

$65.11 /

+0.325 (+0.50%)

, HOLX

Hologic

$68.88 /

+1.17 (+1.73%)

, INGN

Inogen

$27.44 /

-0.75 (-2.66%)

, KYMR

Kymera Therapeutics

$28.76 /

+0.27 (+0.95%)

, NOTV

Inotiv

$21.74 /

+0.68 (+3.23%)

, PEN

Penumbra

$197.58 /

+11.9 (+6.41%)

, RGLS

Regulus

$1.61 /

+0.04 (+2.55%)

, SWAV

ShockWave Medical

$292.67 /

+4.85 (+1.69%)

, WAT

Waters

$308.63 /

+6.55 (+2.17%)

, SUPN

Supernus

$34.53 /

+0.34 (+0.99%)

, ORIC

Oric Pharmaceuticals

$3.56 /

+0.12 (+3.49%)

, PGEN

Precigen

$2.46 /

+0.145 (+6.28%)

, NRIX

Nurix Therapeutics

$15.99 /

-0.13 (-0.81%)

, NUVA

NuVasive

$46.21 /

+0.89 (+1.96%)

, AUTL

Autolus Therapeutics

$3.12 /

+0.19 (+6.48%)

, HALO

Halozyme

$39.63 /

+0.25 (+0.63%)

, IMVT

Immunovant

$5.06 /

+0.145 (+2.95%)

, JNCE

Jounce Therapeutics

$3.49 /

-0.06 (-1.69%)

, IDYA

Ideaya Biosciences

$9.31 /

+0.01 (+0.11%)

, SYK

Stryker

$220.34 /

+9.14 (+4.33%)

, NPCE

NeuroPace

$4.50 /

-0.275 (-5.77%)

, IONS

Ionis Pharmaceuticals

$44.28 /

+0.9 (+2.07%)

, HRMY

Harmony Biosciences

$47.66 /

+1.675 (+3.64%)

2022 Wells Fargo…

2022 Wells Fargo Healthcare Conference to be held in Everett, MA on September 7-9.

ShowHide Related Items >><<
SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

SUPN Supernus
$34.53 /

+0.34 (+0.99%)

RGLS Regulus
$1.61 /

+0.04 (+2.55%)

PGEN Precigen
$2.46 /

+0.145 (+6.28%)

ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

NPCE NeuroPace
$4.50 /

-0.275 (-5.77%)

NOTV Inotiv
$21.74 /

+0.68 (+3.23%)

LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

IONS Ionis Pharmaceuticals
$44.28 /

+0.9 (+2.07%)

INSP Inspire Medical
$197.41 /

+8.2 (+4.33%)

IMVT Immunovant
$5.06 /

+0.145 (+2.95%)

IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

HOLX Hologic
$68.88 /

+1.17 (+1.73%)

HALO Halozyme
$39.63 /

+0.25 (+0.63%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

BNFT Benefitfocus
$6.92 /

-0.13 (-1.84%)

AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

AUTL Autolus Therapeutics
$3.12 /

+0.19 (+6.48%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

03/14/22 JonesTrading
Aveo Pharmaceuticals initiated with a Buy at JonesTrading
BNFT Benefitfocus
$6.92 /

-0.13 (-1.84%)

09/06/22 Piper Sandler
Benefitfocus price target lowered to $6 from $9 at Piper Sandler
06/22/22 Piper Sandler
Benefitfocus downgraded to Neutral from Overweight at Piper Sandler
DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
INSP Inspire Medical
$197.41 /

+8.2 (+4.33%)

08/03/22 Truist
Inspire Medical price target raised to $280 from $250 at Truist
08/03/22 Piper Sandler
Inspire Medical price target lowered to $285 from $310 at Piper Sandler
07/05/22 Piper Sandler
Piper says Inspire appears to have received FDA approval for expanded labeling
06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
GILD Gilead
$65.11 /

+0.325 (+0.50%)

09/02/22 Argus
Gilead pullback provides favorable entry point, says Argus
08/15/22 Piper Sandler
Gilead's Trodelvy shows OS benefit in HR+/HER- BC, says Piper Sandler
08/15/22 Piper Sandler
Gilead price target raised to $74 from $71 at Piper Sandler
08/08/22 Truist
Gilead price target lowered to $71 from $75 at Truist
HOLX Hologic
$68.88 /

+1.17 (+1.73%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
INGN Inogen
$27.44 /

-0.75 (-2.66%)

05/09/22 Stifel
Inogen price target lowered to $30 from $40 at Stifel
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
11/02/21
Fly Intel: Top five analyst upgrades
KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
NOTV Inotiv
$21.74 /

+0.68 (+3.23%)

08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
02/11/22 Lake Street
Inotiv price target raised to $75 from $60 at Lake Street
02/02/22 Craig-Hallum
Inotiv price target raised to $64 from $57 at Craig-Hallum
PEN Penumbra
$197.58 /

+11.9 (+6.41%)

08/05/22 Canaccord
Penumbra price target lowered to $189 from $244 at Canaccord
07/21/22 Deutsche Bank
Penumbra price target lowered to $163 from $250 at Deutsche Bank
07/18/22 BTIG
Penumbra price target lowered to $213 from $272 at BTIG
07/18/22 RBC Capital
Penumbra initiated with an Outperform at RBC Capital
RGLS Regulus
$1.61 /

+0.04 (+2.55%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

09/06/22 Oppenheimer
Oppenheimer downgrades ShockWave Medical to Underperform with $165 price target
09/06/22 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
08/29/22 Piper Sandler
ShockWave Medical price target raised to $338 from $278 at Piper Sandler
08/09/22 Canaccord
ShockWave Medical price target raised to $256 from $232 at Canaccord
WAT Waters
$308.63 /

+6.55 (+2.17%)

08/24/22 Credit Suisse
Waters initiated with a Neutral at Credit Suisse
08/03/22 Baird
Waters price target raised to $348 from $340 at Baird
07/20/22 UBS
Waters initiated with a Neutral at UBS
07/05/22 Evercore ISI
Waters added to 'Tactical Outperform' list at Evercore ISI
SUPN Supernus
$34.53 /

+0.34 (+0.99%)

08/31/22 Piper Sandler
Supernus price target raised to $38 from $33 at Piper Sandler
12/01/21 Jefferies
Supernus resumed with a Buy at Jefferies
10/12/21 JMP Securities
Adamas Pharmaceuticals cut to Market Perform from Outperform at JMP Securities
10/12/21 H.C. Wainwright
Adamas Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

07/15/22 Oppenheimer
Oric Pharmaceuticals assumed with a Perform at Oppenheimer
04/04/22 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/22 H.C. Wainwright
Oric Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
03/22/22 Guggenheim
Oric downgraded to Neutral at Guggenheim after ORIC-101 discontinuation
PGEN Precigen
$2.46 /

+0.145 (+6.28%)

08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

07/11/22 H.C. Wainwright
Nurix Therapeutics price target lowered to $54 from $60 at H.C. Wainwright
07/08/22 Stifel
Nurix Therapeutics price target lowered to $37 from $44 at Stifel
07/08/22 JPMorgan
Nurix Therapeutics price target lowered to $37 from $46 at JPMorgan
07/08/22 Baird
Nurix Therapeutics price target lowered to $32 from $41 at Baird
NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
AUTL Autolus Therapeutics
$3.12 /

+0.19 (+6.48%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
HALO Halozyme
$39.63 /

+0.25 (+0.63%)

08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
IMVT Immunovant
$5.06 /

+0.145 (+2.95%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

08/30/22 Piper Sandler
Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
08/05/22 H.C. Wainwright
Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
05/23/22 Piper Sandler
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler
05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

08/16/22 Baird
Ideaya Biosciences price target lowered to $18 from $26 at Baird
08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
SYK Stryker
$220.34 /

+9.14 (+4.33%)

09/06/22 BTIG
Stryker price target lowered to $238 from $244 at BTIG
07/28/22 Edward Jones
Stryker upgraded to Buy at Edward Jones following pullback
07/28/22 Edward Jones
Stryker upgraded to Buy from Hold at Edward Jones
07/27/22 Wells Fargo
Stryker price target lowered to $237 from $286 at Wells Fargo
NPCE NeuroPace
$4.50 /

-0.275 (-5.77%)

04/05/22 Wolfe Research
NeuroPace initiated with an Outperform at Wolfe Research
01/19/22 Wells Fargo
Wells Fargo downgrades NeuroPace to Equal Weight, lowers price target to $11
01/19/22 Wells Fargo
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
IONS Ionis Pharmaceuticals
$44.28 /

+0.9 (+2.07%)

08/10/22 Citi
Ionis Pharmaceuticals price target raised to $28 from $26 at Citi
07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

09/01/22 Mizuho
Harmony Biosciences recent weakness a buying opportunity, says Mizuho
08/18/22 Mizuho
Harmony Biosciences Orange Book update 'incremental negative,' says Mizuho
08/03/22 Jefferies
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside
08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
WAT Waters
$308.63 /

+6.55 (+2.17%)

SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

SUPN Supernus
$34.53 /

+0.34 (+0.99%)

RGLS Regulus
$1.61 /

+0.04 (+2.55%)

PGEN Precigen
$2.46 /

+0.145 (+6.28%)

PEN Penumbra
$197.58 /

+11.9 (+6.41%)

ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

NPCE NeuroPace
$4.50 /

-0.275 (-5.77%)

LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

IONS Ionis Pharmaceuticals
$44.28 /

+0.9 (+2.07%)

INSP Inspire Medical
$197.41 /

+8.2 (+4.33%)

INGN Inogen
$27.44 /

-0.75 (-2.66%)

IMVT Immunovant
$5.06 /

+0.145 (+2.95%)

IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

HOLX Hologic
$68.88 /

+1.17 (+1.73%)

HALO Halozyme
$39.63 /

+0.25 (+0.63%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

BNFT Benefitfocus
$6.92 /

-0.13 (-1.84%)

AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

AUTL Autolus Therapeutics
$3.12 /

+0.19 (+6.48%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

  • 12
    Aug
  • 27
    Jul
  • 16
    Dec
SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

SYK Stryker
$220.34 /

+9.14 (+4.33%)

SWAV ShockWave Medical
$292.67 /

+4.85 (+1.69%)

SUPN Supernus
$34.53 /

+0.34 (+0.99%)

PEN Penumbra
$197.58 /

+11.9 (+6.41%)

ORIC Oric Pharmaceuticals
$3.56 /

+0.12 (+3.49%)

NUVA NuVasive
$46.21 /

+0.89 (+1.96%)

NRIX Nurix Therapeutics
$15.99 /

-0.13 (-0.81%)

LEGN Legend Biotech
$43.61 /

-0.25 (-0.57%)

KYMR Kymera Therapeutics
$28.76 /

+0.27 (+0.95%)

JNCE Jounce Therapeutics
$3.49 /

-0.06 (-1.69%)

IDYA Ideaya Biosciences
$9.31 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$47.66 /

+1.675 (+3.64%)

HOLX Hologic
$68.88 /

+1.17 (+1.73%)

HALO Halozyme
$39.63 /

+0.25 (+0.63%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

FATE Fate Therapeutics
$28.25 /

+0.935 (+3.42%)

DGX Quest Diagnostics
$130.17 /

+2.86 (+2.25%)

AVEO Aveo Pharmaceuticals
$8.59 /

+0.28 (+3.37%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

WAT Waters
$308.63 /

+6.55 (+2.17%)

SYK Stryker
$220.34 /

+9.14 (+4.33%)

GILD Gilead
$65.11 /

+0.325 (+0.50%)

ABBV AbbVie
$140.52 /

+1.48 (+1.06%)

Conference/Events
Wells Fargo to hold a conference » 04:55
09/08/22
09/08
04:55
09/08/22
04:55
ABBV

AbbVie

$139.04 /

+1.4 (+1.02%)

, AVEO

Aveo Pharmaceuticals

$8.31 /

+0.33 (+4.14%)

, BNFT

Benefitfocus

$7.04 /

+0.33 (+4.92%)

, DGX

Quest Diagnostics

$127.38 /

+2.27 (+1.81%)

, FATE

Fate Therapeutics

$27.31 /

+2.02 (+7.99%)

, INSP

Inspire Medical

$188.93 /

+5.92 (+3.23%)

, LEGN

Legend Biotech

$43.86 /

-0.17 (-0.39%)

, GILD

Gilead

$64.79 /

+1.355 (+2.14%)

, HOLX

Hologic

$67.71 /

+0.33 (+0.49%)

, INGN

Inogen

$28.19 /

+0.6 (+2.17%)

, KYMR

Kymera Therapeutics

$28.47 /

+2.545 (+9.82%)

, NOTV

Inotiv

$20.88 /

+0.24 (+1.16%)

, PEN

Penumbra

$186.16 /

+21.935 (+13.36%)

, RGLS

Regulus

$1.57 /

-0.01 (-0.63%)

, SWAV

ShockWave Medical

$286.96 /

+12.165 (+4.43%)

, WAT

Waters

$302.21 /

+4.705 (+1.58%)

, SUPN

Supernus

$34.19 /

+0.15 (+0.44%)

, ORIC

Oric Pharmaceuticals

$3.46 /

-0.09 (-2.54%)

, PGEN

Precigen

$2.31 /

+0.025 (+1.09%)

, NRIX

Nurix Therapeutics

$16.12 /

+0.83 (+5.43%)

, NUVA

NuVasive

$45.32 /

+2.34 (+5.44%)

, AUTL

Autolus Therapeutics

$2.94 /

-0.15 (-4.85%)

, HALO

Halozyme

$39.39 /

+0.845 (+2.19%)

, IMVT

Immunovant

$4.92 /

+0.03 (+0.61%)

, JNCE

Jounce Therapeutics

$3.55 /

+0.05 (+1.43%)

, IDYA

Ideaya Biosciences

$9.29 /

+0.05 (+0.54%)

, SYK

Stryker

$211.20 /

+8.39 (+4.14%)

, NPCE

NeuroPace

$4.73 /

+0.01 (+0.21%)

, IONS

Ionis Pharmaceuticals

$43.43 /

+1.75 (+4.20%)

, HRMY

Harmony Biosciences

$46.06 /

+1.7 (+3.83%)

2022 Wells Fargo…

2022 Wells Fargo Healthcare Conference to be held in Everett, MA on September 7-9.

ShowHide Related Items >><<
SYK Stryker
$211.20 /

+8.39 (+4.14%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

SUPN Supernus
$34.19 /

+0.15 (+0.44%)

RGLS Regulus
$1.57 /

-0.01 (-0.63%)

PGEN Precigen
$2.31 /

+0.025 (+1.09%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

NOTV Inotiv
$20.88 /

+0.24 (+1.16%)

LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

IONS Ionis Pharmaceuticals
$43.43 /

+1.75 (+4.20%)

INSP Inspire Medical
$188.93 /

+5.92 (+3.23%)

IMVT Immunovant
$4.92 /

+0.03 (+0.61%)

IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

HOLX Hologic
$67.71 /

+0.33 (+0.49%)

HALO Halozyme
$39.39 /

+0.845 (+2.19%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

BNFT Benefitfocus
$7.04 /

+0.33 (+4.92%)

AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

AUTL Autolus Therapeutics
$2.94 /

-0.15 (-4.85%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

03/14/22 JonesTrading
Aveo Pharmaceuticals initiated with a Buy at JonesTrading
BNFT Benefitfocus
$7.04 /

+0.33 (+4.92%)

09/06/22 Piper Sandler
Benefitfocus price target lowered to $6 from $9 at Piper Sandler
06/22/22 Piper Sandler
Benefitfocus downgraded to Neutral from Overweight at Piper Sandler
DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
INSP Inspire Medical
$188.93 /

+5.92 (+3.23%)

08/03/22 Truist
Inspire Medical price target raised to $280 from $250 at Truist
08/03/22 Piper Sandler
Inspire Medical price target lowered to $285 from $310 at Piper Sandler
07/05/22 Piper Sandler
Piper says Inspire appears to have received FDA approval for expanded labeling
06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
GILD Gilead
$64.79 /

+1.355 (+2.14%)

09/02/22 Argus
Gilead pullback provides favorable entry point, says Argus
08/15/22 Piper Sandler
Gilead's Trodelvy shows OS benefit in HR+/HER- BC, says Piper Sandler
08/15/22 Piper Sandler
Gilead price target raised to $74 from $71 at Piper Sandler
08/08/22 Truist
Gilead price target lowered to $71 from $75 at Truist
HOLX Hologic
$67.71 /

+0.33 (+0.49%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
INGN Inogen
$28.19 /

+0.6 (+2.17%)

05/09/22 Stifel
Inogen price target lowered to $30 from $40 at Stifel
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
11/02/21
Fly Intel: Top five analyst upgrades
KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
NOTV Inotiv
$20.88 /

+0.24 (+1.16%)

08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
02/11/22 Lake Street
Inotiv price target raised to $75 from $60 at Lake Street
02/02/22 Craig-Hallum
Inotiv price target raised to $64 from $57 at Craig-Hallum
PEN Penumbra
$186.16 /

+21.935 (+13.36%)

08/05/22 Canaccord
Penumbra price target lowered to $189 from $244 at Canaccord
07/21/22 Deutsche Bank
Penumbra price target lowered to $163 from $250 at Deutsche Bank
07/18/22 BTIG
Penumbra price target lowered to $213 from $272 at BTIG
07/18/22 RBC Capital
Penumbra initiated with an Outperform at RBC Capital
RGLS Regulus
$1.57 /

-0.01 (-0.63%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

09/06/22 Oppenheimer
Oppenheimer downgrades ShockWave Medical to Underperform with $165 price target
09/06/22 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
08/29/22 Piper Sandler
ShockWave Medical price target raised to $338 from $278 at Piper Sandler
08/09/22 Canaccord
ShockWave Medical price target raised to $256 from $232 at Canaccord
WAT Waters
$302.21 /

+4.705 (+1.58%)

08/24/22 Credit Suisse
Waters initiated with a Neutral at Credit Suisse
08/03/22 Baird
Waters price target raised to $348 from $340 at Baird
07/20/22 UBS
Waters initiated with a Neutral at UBS
07/05/22 Evercore ISI
Waters added to 'Tactical Outperform' list at Evercore ISI
SUPN Supernus
$34.19 /

+0.15 (+0.44%)

08/31/22 Piper Sandler
Supernus price target raised to $38 from $33 at Piper Sandler
12/01/21 Jefferies
Supernus resumed with a Buy at Jefferies
10/12/21 JMP Securities
Adamas Pharmaceuticals cut to Market Perform from Outperform at JMP Securities
10/12/21 H.C. Wainwright
Adamas Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

07/15/22 Oppenheimer
Oric Pharmaceuticals assumed with a Perform at Oppenheimer
04/04/22 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/22 H.C. Wainwright
Oric Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
03/22/22 Guggenheim
Oric downgraded to Neutral at Guggenheim after ORIC-101 discontinuation
PGEN Precigen
$2.31 /

+0.025 (+1.09%)

08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

07/11/22 H.C. Wainwright
Nurix Therapeutics price target lowered to $54 from $60 at H.C. Wainwright
07/08/22 Stifel
Nurix Therapeutics price target lowered to $37 from $44 at Stifel
07/08/22 JPMorgan
Nurix Therapeutics price target lowered to $37 from $46 at JPMorgan
07/08/22 Baird
Nurix Therapeutics price target lowered to $32 from $41 at Baird
NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
AUTL Autolus Therapeutics
$2.94 /

-0.15 (-4.85%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
HALO Halozyme
$39.39 /

+0.845 (+2.19%)

08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
IMVT Immunovant
$4.92 /

+0.03 (+0.61%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

08/30/22 Piper Sandler
Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
08/05/22 H.C. Wainwright
Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
05/23/22 Piper Sandler
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler
05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

08/16/22 Baird
Ideaya Biosciences price target lowered to $18 from $26 at Baird
08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
SYK Stryker
$211.20 /

+8.39 (+4.14%)

09/06/22 BTIG
Stryker price target lowered to $238 from $244 at BTIG
07/28/22 Edward Jones
Stryker upgraded to Buy at Edward Jones following pullback
07/28/22 Edward Jones
Stryker upgraded to Buy from Hold at Edward Jones
07/27/22 Wells Fargo
Stryker price target lowered to $237 from $286 at Wells Fargo
NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

04/05/22 Wolfe Research
NeuroPace initiated with an Outperform at Wolfe Research
01/19/22 Wells Fargo
Wells Fargo downgrades NeuroPace to Equal Weight, lowers price target to $11
01/19/22 Wells Fargo
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
IONS Ionis Pharmaceuticals
$43.43 /

+1.75 (+4.20%)

08/10/22 Citi
Ionis Pharmaceuticals price target raised to $28 from $26 at Citi
07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

09/01/22 Mizuho
Harmony Biosciences recent weakness a buying opportunity, says Mizuho
08/18/22 Mizuho
Harmony Biosciences Orange Book update 'incremental negative,' says Mizuho
08/03/22 Jefferies
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside
08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
WAT Waters
$302.21 /

+4.705 (+1.58%)

SYK Stryker
$211.20 /

+8.39 (+4.14%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

SUPN Supernus
$34.19 /

+0.15 (+0.44%)

RGLS Regulus
$1.57 /

-0.01 (-0.63%)

PGEN Precigen
$2.31 /

+0.025 (+1.09%)

PEN Penumbra
$186.16 /

+21.935 (+13.36%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

IONS Ionis Pharmaceuticals
$43.43 /

+1.75 (+4.20%)

INSP Inspire Medical
$188.93 /

+5.92 (+3.23%)

INGN Inogen
$28.19 /

+0.6 (+2.17%)

IMVT Immunovant
$4.92 /

+0.03 (+0.61%)

IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

HOLX Hologic
$67.71 /

+0.33 (+0.49%)

HALO Halozyme
$39.39 /

+0.845 (+2.19%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

BNFT Benefitfocus
$7.04 /

+0.33 (+4.92%)

AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

AUTL Autolus Therapeutics
$2.94 /

-0.15 (-4.85%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

  • 12
    Aug
  • 27
    Jul
  • 16
    Dec
SYK Stryker
$211.20 /

+8.39 (+4.14%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

SYK Stryker
$211.20 /

+8.39 (+4.14%)

SWAV ShockWave Medical
$286.96 /

+12.165 (+4.43%)

SUPN Supernus
$34.19 /

+0.15 (+0.44%)

PEN Penumbra
$186.16 /

+21.935 (+13.36%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.32 /

+2.34 (+5.44%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

LEGN Legend Biotech
$43.86 /

-0.17 (-0.39%)

KYMR Kymera Therapeutics
$28.47 /

+2.545 (+9.82%)

JNCE Jounce Therapeutics
$3.55 /

+0.05 (+1.43%)

IDYA Ideaya Biosciences
$9.29 /

+0.05 (+0.54%)

HRMY Harmony Biosciences
$46.06 /

+1.7 (+3.83%)

HOLX Hologic
$67.71 /

+0.33 (+0.49%)

HALO Halozyme
$39.39 /

+0.845 (+2.19%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

FATE Fate Therapeutics
$27.31 /

+2.02 (+7.99%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

AVEO Aveo Pharmaceuticals
$8.31 /

+0.33 (+4.14%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

WAT Waters
$302.21 /

+4.705 (+1.58%)

SYK Stryker
$211.20 /

+8.39 (+4.14%)

GILD Gilead
$64.79 /

+1.355 (+2.14%)

ABBV AbbVie
$139.04 /

+1.4 (+1.02%)

Hot Stocks
Quest Diagnostics' proprietary monkeypox text receives EUA from FDA » 19:17
09/07/22
09/07
19:17
09/07/22
19:17
DGX

Quest Diagnostics

$127.38 /

+2.27 (+1.81%)

Quest Diagnostics…

Quest Diagnostics announced that it has received emergency use authorization from the U.S. Food and Drug Administration for the company's lab-developed molecular diagnostic test to aid in the diagnosis of infection with the Monkeypox virus. The EUA is the first granted to a commercially available monkeypox test in the United States. On September 7, the Department of Health and Human Services declared that the public health emergency countermeasures now extend to monkeypox testing. "Quest is committed to developing high-quality diagnostic innovations to help respond to the monkeypox public health emergency," said Jay G. Wohlgemuth, M.D., Senior Vice President, R&D, Medical and Chief Medical Officer, Quest Diagnostics. "With this FDA emergency authorization, Quest is positioned to complement the response of public health laboratories and help fight the spread of the virus."

ShowHide Related Items >><<
DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

DGX Quest Diagnostics
$127.38 /

+2.27 (+1.81%)

Conference/Events
Wells Fargo to hold a conference » 16:08
09/07/22
09/07
16:08
09/07/22
16:08
ABBV

AbbVie

$138.72 /

+1.08 (+0.78%)

, AVEO

Aveo Pharmaceuticals

$8.35 /

+0.37 (+4.64%)

, BNFT

Benefitfocus

$7.02 /

+0.31 (+4.62%)

, DGX

Quest Diagnostics

$127.43 /

+2.325 (+1.86%)

, FATE

Fate Therapeutics

$27.32 /

+2.03 (+8.03%)

, INSP

Inspire Medical

$188.51 /

+5.5 (+3.01%)

, LEGN

Legend Biotech

$43.82 /

-0.21 (-0.48%)

, GILD

Gilead

$64.88 /

+1.45 (+2.29%)

, HOLX

Hologic

$67.72 /

+0.34 (+0.50%)

, INGN

Inogen

$28.45 /

+0.86 (+3.12%)

, KYMR

Kymera Therapeutics

$28.48 /

+2.555 (+9.86%)

, NOTV

Inotiv

$21.03 /

+0.39 (+1.89%)

, PEN

Penumbra

$184.98 /

+20.76 (+12.64%)

, RGLS

Regulus

$1.54 /

-0.04 (-2.53%)

, SWAV

ShockWave Medical

$287.16 /

+12.37 (+4.50%)

, WAT

Waters

$302.39 /

+4.89 (+1.64%)

, SUPN

Supernus

$34.11 /

+0.07 (+0.21%)

, ORIC

Oric Pharmaceuticals

$3.46 /

-0.09 (-2.54%)

, PGEN

Precigen

$2.31 /

+0.02 (+0.88%)

, NRIX

Nurix Therapeutics

$16.12 /

+0.83 (+5.43%)

, NUVA

NuVasive

$45.25 /

+2.27 (+5.28%)

, AUTL

Autolus Therapeutics

$2.93 /

-0.16 (-5.18%)

, HALO

Halozyme

$39.40 /

+0.855 (+2.22%)

, IMVT

Immunovant

$4.95 /

+0.06 (+1.23%)

, JNCE

Jounce Therapeutics

$3.61 /

+0.11 (+3.14%)

, IDYA

Ideaya Biosciences

$9.25 /

+0.01 (+0.11%)

, SYK

Stryker

$210.95 /

+8.14 (+4.01%)

, NPCE

NeuroPace

$4.73 /

+0.01 (+0.21%)

, IONS

Ionis Pharmaceuticals

$43.27 /

+1.585 (+3.80%)

, HRMY

Harmony Biosciences

$45.98 /

+1.62 (+3.65%)

2022 Wells Fargo…

2022 Wells Fargo Healthcare Conference to be held in Everett, MA on September 7-9.

ShowHide Related Items >><<
SYK Stryker
$210.95 /

+8.14 (+4.01%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

SUPN Supernus
$34.11 /

+0.07 (+0.21%)

RGLS Regulus
$1.54 /

-0.04 (-2.53%)

PGEN Precigen
$2.31 /

+0.02 (+0.88%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

NOTV Inotiv
$21.03 /

+0.39 (+1.89%)

LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

IONS Ionis Pharmaceuticals
$43.27 /

+1.585 (+3.80%)

INSP Inspire Medical
$188.51 /

+5.5 (+3.01%)

IMVT Immunovant
$4.95 /

+0.06 (+1.23%)

IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

HOLX Hologic
$67.72 /

+0.34 (+0.50%)

HALO Halozyme
$39.40 /

+0.855 (+2.22%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

BNFT Benefitfocus
$7.02 /

+0.31 (+4.62%)

AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

AUTL Autolus Therapeutics
$2.93 /

-0.16 (-5.18%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

08/30/22 Piper Sandler
I-Mab price target lowered to $30 from $35 at Piper Sandler
08/24/22 Argus
AbbVie price target lowered to $155 from $165 at Argus
08/01/22 JPMorgan
AbbVie selloff Friday a buying opportunity, says JPMorgan
08/01/22 Barclays
AbbVie price target lowered to $160 from $174 at Barclays
AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

03/14/22 JonesTrading
Aveo Pharmaceuticals initiated with a Buy at JonesTrading
BNFT Benefitfocus
$7.02 /

+0.31 (+4.62%)

09/06/22 Piper Sandler
Benefitfocus price target lowered to $6 from $9 at Piper Sandler
06/22/22 Piper Sandler
Benefitfocus downgraded to Neutral from Overweight at Piper Sandler
DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

08/18/22 Wells Fargo
Fate Therapeutics assumed with an Overweight at Wells Fargo
08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
INSP Inspire Medical
$188.51 /

+5.5 (+3.01%)

08/03/22 Truist
Inspire Medical price target raised to $280 from $250 at Truist
08/03/22 Piper Sandler
Inspire Medical price target lowered to $285 from $310 at Piper Sandler
07/05/22 Piper Sandler
Piper says Inspire appears to have received FDA approval for expanded labeling
06/10/22 Truist
Inspire Medical price target lowered to $250 from $296 at Truist
LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

07/20/22 Canaccord
Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
06/16/22 BMO Capital
Legend Biotech initiated with an Outperform at BMO Capital
05/31/22 Morgan Stanley
Legend Biotech named Catalyst Driven Idea by Morgan Stanley
03/15/22 Barclays
Legend Biotech initiated with an Overweight at Barclays
GILD Gilead
$64.88 /

+1.45 (+2.29%)

09/02/22 Argus
Gilead pullback provides favorable entry point, says Argus
08/15/22 Piper Sandler
Gilead's Trodelvy shows OS benefit in HR+/HER- BC, says Piper Sandler
08/15/22 Piper Sandler
Gilead price target raised to $74 from $71 at Piper Sandler
08/08/22 Truist
Gilead price target lowered to $71 from $75 at Truist
HOLX Hologic
$67.72 /

+0.34 (+0.50%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
INGN Inogen
$28.45 /

+0.86 (+3.12%)

05/09/22 Stifel
Inogen price target lowered to $30 from $40 at Stifel
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
12/09/21 Needham
Inogen upgraded to Buy from Hold at Needham
11/02/21
Fly Intel: Top five analyst upgrades
KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

08/31/22 JPMorgan
Kymera selloff a 'misplaced knee-jerk reaction,' says JPMorgan
08/15/22 Jefferies
Kymera Therapeutics initiated with a Buy at Jefferies
08/03/22 Goldman Sachs
Kymera Therapeutics initiated with a Buy at Goldman Sachs
07/20/22 SVB Securities
Kymera Therapeutics initiated with a Market Perform at SVB Securities
NOTV Inotiv
$21.03 /

+0.39 (+1.89%)

08/11/22 Lake Street
Inotiv price target raised to $60 from $50 at Lake Street
06/14/22 Lake Street
Inotiv price target lowered to $50 from $75 at Lake Street
02/11/22 Lake Street
Inotiv price target raised to $75 from $60 at Lake Street
02/02/22 Craig-Hallum
Inotiv price target raised to $64 from $57 at Craig-Hallum
PEN Penumbra
$184.98 /

+20.76 (+12.64%)

08/05/22 Canaccord
Penumbra price target lowered to $189 from $244 at Canaccord
07/21/22 Deutsche Bank
Penumbra price target lowered to $163 from $250 at Deutsche Bank
07/18/22 BTIG
Penumbra price target lowered to $213 from $272 at BTIG
07/18/22 RBC Capital
Penumbra initiated with an Outperform at RBC Capital
RGLS Regulus
$1.54 /

-0.04 (-2.53%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

09/06/22 Oppenheimer
Oppenheimer downgrades ShockWave Medical to Underperform with $165 price target
09/06/22 Oppenheimer
ShockWave Medical downgraded to Underperform from Perform at Oppenheimer
08/29/22 Piper Sandler
ShockWave Medical price target raised to $338 from $278 at Piper Sandler
08/09/22 Canaccord
ShockWave Medical price target raised to $256 from $232 at Canaccord
WAT Waters
$302.39 /

+4.89 (+1.64%)

08/24/22 Credit Suisse
Waters initiated with a Neutral at Credit Suisse
08/03/22 Baird
Waters price target raised to $348 from $340 at Baird
07/20/22 UBS
Waters initiated with a Neutral at UBS
07/05/22 Evercore ISI
Waters added to 'Tactical Outperform' list at Evercore ISI
SUPN Supernus
$34.11 /

+0.07 (+0.21%)

08/31/22 Piper Sandler
Supernus price target raised to $38 from $33 at Piper Sandler
12/01/21 Jefferies
Supernus resumed with a Buy at Jefferies
10/12/21 JMP Securities
Adamas Pharmaceuticals cut to Market Perform from Outperform at JMP Securities
10/12/21 H.C. Wainwright
Adamas Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

07/15/22 Oppenheimer
Oric Pharmaceuticals assumed with a Perform at Oppenheimer
04/04/22 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/22 H.C. Wainwright
Oric Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
03/22/22 Guggenheim
Oric downgraded to Neutral at Guggenheim after ORIC-101 discontinuation
PGEN Precigen
$2.31 /

+0.02 (+0.88%)

08/09/22 H.C. Wainwright
Precigen price target lowered to $6 from $10 at H.C. Wainwright
07/05/22 Stifel
Precigen subsidiary sale relieves convertible debt overhang, says Stifel
NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

07/11/22 H.C. Wainwright
Nurix Therapeutics price target lowered to $54 from $60 at H.C. Wainwright
07/08/22 Stifel
Nurix Therapeutics price target lowered to $37 from $44 at Stifel
07/08/22 JPMorgan
Nurix Therapeutics price target lowered to $37 from $46 at JPMorgan
07/08/22 Baird
Nurix Therapeutics price target lowered to $32 from $41 at Baird
NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
06/28/22 Stifel
Stifel cuts Orthofix target, says momentum 'faded' during Q2
AUTL Autolus Therapeutics
$2.93 /

-0.16 (-5.18%)

06/14/22 Truist
Autolus Therapeutics price target lowered to $11 from $13 at Truist
12/30/21 Mizuho
Mizuho announces top oncology stock picks for 2022
12/20/21 H.C. Wainwright
Autolus Therapeutics price target lowered to $11 from $13 at H.C. Wainwright
HALO Halozyme
$39.40 /

+0.855 (+2.22%)

08/10/22 Benchmark
Halozyme recent weakness a buying opportunity, says Benchmark
05/23/22 SVB Securities
Halozyme initiated with an Outperform at SVB Leerink
04/14/22 Truist
Antares Pharma downgraded to Hold from Buy at Truist
04/14/22 Raymond James
Antares Pharma downgraded to Market Perform from Strong Buy at Raymond James
IMVT Immunovant
$4.95 /

+0.06 (+1.23%)

03/30/22 Chardan
Immunovant price target lowered to $14 from $20 at Chardan
01/05/22 Chardan
Immunovant price target lowered to $20 from $22 at Chardan
12/31/21 Wells Fargo
Immunovant shares to remain range-bound in 2022, says Wells Fargo
12/08/21 Wells Fargo
Immunovant initiated with an Equal Weight at Wells Fargo
JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

08/30/22 Piper Sandler
Jounce Therapeutics price target lowered to $6 from $9 at Piper Sandler
08/05/22 H.C. Wainwright
Jounce Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
05/23/22 Piper Sandler
Jounce Therapeutics price target lowered to $9 from $17 at Piper Sandler
05/12/22 Roth Capital
Jounce Therapeutics recent pullback overdone, says Roth Capital
IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

08/16/22 Baird
Ideaya Biosciences price target lowered to $18 from $26 at Baird
08/16/22 Oppenheimer
Ideaya Biosciences price target lowered to $20 from $25 at Oppenheimer
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold at Stifel after GSK waives IDE397 opt-in
08/15/22 Stifel
Ideaya Biosciences downgraded to Hold from Buy at Stifel
SYK Stryker
$210.95 /

+8.14 (+4.01%)

09/06/22 BTIG
Stryker price target lowered to $238 from $244 at BTIG
07/28/22 Edward Jones
Stryker upgraded to Buy at Edward Jones following pullback
07/28/22 Edward Jones
Stryker upgraded to Buy from Hold at Edward Jones
07/27/22 Wells Fargo
Stryker price target lowered to $237 from $286 at Wells Fargo
NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

04/05/22 Wolfe Research
NeuroPace initiated with an Outperform at Wolfe Research
01/19/22 Wells Fargo
Wells Fargo downgrades NeuroPace to Equal Weight, lowers price target to $11
01/19/22 Wells Fargo
NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo
01/07/22 Morgan Stanley
NeuroPace cut to Underweight at Morgan Stanley on cloudy near-term outlook
IONS Ionis Pharmaceuticals
$43.27 /

+1.585 (+3.80%)

08/10/22 Citi
Ionis Pharmaceuticals price target raised to $28 from $26 at Citi
07/26/22 Piper Sandler
Ionis Pharmaceuticals price target raised to $58 from $55 at Piper Sandler
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/18/22 Oppenheimer
Ionis Pharmaceuticals assumed with an Outperform at Oppenheimer
HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

09/01/22 Mizuho
Harmony Biosciences recent weakness a buying opportunity, says Mizuho
08/18/22 Mizuho
Harmony Biosciences Orange Book update 'incremental negative,' says Mizuho
08/03/22 Jefferies
Jefferies downgrades Harmony Biosciences to Hold, sees limited near-term upside
08/03/22 Oppenheimer
Harmony Biosciences price target raised to $67 from $62 at Oppenheimer
WAT Waters
$302.39 /

+4.89 (+1.64%)

SYK Stryker
$210.95 /

+8.14 (+4.01%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

SUPN Supernus
$34.11 /

+0.07 (+0.21%)

RGLS Regulus
$1.54 /

-0.04 (-2.53%)

PGEN Precigen
$2.31 /

+0.02 (+0.88%)

PEN Penumbra
$184.98 /

+20.76 (+12.64%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

NPCE NeuroPace
$4.73 /

+0.01 (+0.21%)

LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

IONS Ionis Pharmaceuticals
$43.27 /

+1.585 (+3.80%)

INSP Inspire Medical
$188.51 /

+5.5 (+3.01%)

INGN Inogen
$28.45 /

+0.86 (+3.12%)

IMVT Immunovant
$4.95 /

+0.06 (+1.23%)

IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

HOLX Hologic
$67.72 /

+0.34 (+0.50%)

HALO Halozyme
$39.40 /

+0.855 (+2.22%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

BNFT Benefitfocus
$7.02 /

+0.31 (+4.62%)

AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

AUTL Autolus Therapeutics
$2.93 /

-0.16 (-5.18%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

  • 12
    Aug
  • 27
    Jul
  • 16
    Dec
SYK Stryker
$210.95 /

+8.14 (+4.01%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

SYK Stryker
$210.95 /

+8.14 (+4.01%)

SWAV ShockWave Medical
$287.16 /

+12.37 (+4.50%)

SUPN Supernus
$34.11 /

+0.07 (+0.21%)

PEN Penumbra
$184.98 /

+20.76 (+12.64%)

ORIC Oric Pharmaceuticals
$3.46 /

-0.09 (-2.54%)

NUVA NuVasive
$45.25 /

+2.27 (+5.28%)

NRIX Nurix Therapeutics
$16.12 /

+0.83 (+5.43%)

LEGN Legend Biotech
$43.82 /

-0.21 (-0.48%)

KYMR Kymera Therapeutics
$28.48 /

+2.555 (+9.86%)

JNCE Jounce Therapeutics
$3.61 /

+0.11 (+3.14%)

IDYA Ideaya Biosciences
$9.25 /

+0.01 (+0.11%)

HRMY Harmony Biosciences
$45.98 /

+1.62 (+3.65%)

HOLX Hologic
$67.72 /

+0.34 (+0.50%)

HALO Halozyme
$39.40 /

+0.855 (+2.22%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

FATE Fate Therapeutics
$27.32 /

+2.03 (+8.03%)

DGX Quest Diagnostics
$127.43 /

+2.325 (+1.86%)

AVEO Aveo Pharmaceuticals
$8.35 /

+0.37 (+4.64%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

WAT Waters
$302.39 /

+4.89 (+1.64%)

SYK Stryker
$210.95 /

+8.14 (+4.01%)

GILD Gilead
$64.88 /

+1.45 (+2.29%)

ABBV AbbVie
$138.72 /

+1.08 (+0.78%)

Over a month ago
On The Fly
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:56
08/22/22
08/22
09:56
08/22/22
09:56
ELV

Elevance Health

$508.26 /

+4.55 (+0.90%)

, VIPS

Vipshop

$10.51 /

+0.53 (+5.31%)

, SNDR

Schneider National

$24.69 /

-0.12 (-0.48%)

, KNX

Knight-Swift

$54.50 /

-0.99 (-1.78%)

, BRKR

Bruker

$59.78 /

+0.12 (+0.20%)

, DAO

Youdao

$5.38 /

+0.24 (+4.67%)

, NFLX

Netflix

$228.15 /

-13.26 (-5.49%)

, UPS

UPS

$205.65 /

-2.92 (-1.40%)

, COUP

Coupa Software

$65.05 /

-2.72 (-4.01%)

, DOCU

DocuSign

$63.80 /

-2.155 (-3.27%)

, SAIA

Saia

$219.34 /

-8.52 (-3.74%)

, LH

Labcorp

$248.21 /

-1.13 (-0.45%)

, DGX

Quest Diagnostics

$135.11 /

-0.39 (-0.29%)

, WALD

Waldencast Acquisition

$8.94 /

+ (+0.00%)

, PGPHF

Partners Group

$991.35 /

-48.69 (-4.68%)

, CINC

CinCor Pharma

$33.11 /

-0.21 (-0.63%)

Institutional investors…

ShowHide Related Items >><<
WALD Waldencast Acquisition
$8.94 /

+ (+0.00%)

VIPS Vipshop
$10.51 /

+0.53 (+5.31%)

UPS UPS
$205.65 /

-2.92 (-1.40%)

SNDR Schneider National
$24.69 /

-0.12 (-0.48%)

SAIA Saia
$219.34 /

-8.52 (-3.74%)

PGPHF Partners Group
$991.35 /

-48.69 (-4.68%)

NFLX Netflix
$228.15 /

-13.26 (-5.49%)

LH Labcorp
$248.21 /

-1.13 (-0.45%)

KNX Knight-Swift
$54.50 /

-0.99 (-1.78%)

ELV Elevance Health
$508.26 /

+4.55 (+0.90%)

DOCU DocuSign
$63.80 /

-2.155 (-3.27%)

DGX Quest Diagnostics
$135.11 /

-0.39 (-0.29%)

DAO Youdao
$5.38 /

+0.24 (+4.67%)

COUP Coupa Software
$65.05 /

-2.72 (-4.01%)

CINC CinCor Pharma
$33.11 /

-0.21 (-0.63%)

BRKR Bruker
$59.78 /

+0.12 (+0.20%)

ELV Elevance Health
$508.26 /

+4.55 (+0.90%)

08/22/22 SVB Securities
SVB Securities upgrades Elevance Health to Outperform, raises target to $580
08/22/22 SVB Securities
Elevance Health upgraded to Outperform from Market Perform at SVB Securities
07/28/22 Wells Fargo
Elevance Health price target lowered to $557 from $580 at Wells Fargo
07/22/22 SVB Securities
Elevance Health price target lowered to $490 from $555 at SVB Securities
VIPS Vipshop
$10.51 /

+0.53 (+5.31%)

08/22/22 Credit Suisse
Vipshop upgraded to Outperform on 'expedited' growth at Credit Suisse
08/22/22 Citi
Vipshop upgraded to Neutral from Sell at Citi
08/22/22 Credit Suisse
Vipshop upgraded to Outperform from Neutral at Credit Suisse
08/19/22 Benchmark
Vipshop Q2 results 'better than feared,' says Benchmark
SNDR Schneider National
$24.69 /

-0.12 (-0.48%)

08/22/22 Evercore ISI
Evercore upgrades Schneider to Outperform on attractive risk/reward
08/22/22 Evercore ISI
Schneider National upgraded to Outperform from In Line at Evercore ISI
07/12/22 Evercore ISI
Schneider National price target lowered to $27 from $29 at Evercore ISI
06/27/22 Credit Suisse
Schneider National initiated with an Outperform at Credit Suisse
KNX Knight-Swift
$54.50 /

-0.99 (-1.78%)

07/21/22 Susquehanna
Knight-Swift price target raised to $65 from $64 at Susquehanna
07/12/22 Stifel
Stifel sees 'strong' Q2 for Knight-Swift, trims target to $67
07/12/22 Evercore ISI
Knight-Swift upgraded to Outperform from In Line at Evercore ISI
BRKR Bruker
$59.78 /

+0.12 (+0.20%)

08/22/22 Citi
Bruker upgraded to Buy from Neutral at Citi
10/14/21 Cowen
Bruker coverage transferred at Cowen
DAO Youdao
$5.38 /

+0.24 (+4.67%)

08/22/22 CICC
Youdao upgraded to Outperform from Market Perform at CICC
07/29/22 Jefferies
Youdao price target lowered to $5.20 from $13 at Jefferies
07/29/22 Citi
Youdao price target lowered to $7.80 from $15.50 at Citi
03/07/22 Morgan Stanley
Youdao upgraded to Overweight from Equal Weight at Morgan Stanley
NFLX Netflix
$228.15 /

-13.26 (-5.49%)

08/22/22 CFRA
Netflix downgraded to Sell from Hold at CFRA
08/11/22 Wells Fargo
Disney price target raised to $145 from $130 at Wells Fargo
08/10/22 Oppenheimer
Trade Desk price target raised to $78 from $60 at Oppenheimer
08/09/22 JPMorgan
Netflix shares up 16% since earnings on narrative shift, says JPMorgan
UPS UPS
$205.65 /

-2.92 (-1.40%)

08/22/22 Evercore ISI
UPS downgraded to In Line from Outperform at Evercore ISI
07/27/22 Wells Fargo
UPS price target lowered to $223 from $270 at Wells Fargo
07/27/22 Raymond James
UPS price target lowered to $220 from $225 at Raymond James
07/27/22 Barclays
UPS price target lowered to $200 from $220 at Barclays
COUP Coupa Software
$65.05 /

-2.72 (-4.01%)

08/22/22 UBS
Coupa Software price target lowered to $76 from $84 at UBS
08/22/22 RBC Capital
Coupa Software downgraded to Underperform from Sector Perform at RBC Capital
07/18/22 Piper Sandler
Coupa Software price target lowered to $65 from $85 at Piper Sandler
07/15/22 Evercore ISI
CVS Health, Coupa added to 'Best SMID Core Ideas' list at Evercore ISI
DOCU DocuSign
$63.80 /

-2.155 (-3.27%)

08/22/22 RBC Capital
DocuSign downgraded to Sector Perform from Outperform at RBC Capital
07/21/22 Piper Sandler
DocuSign downgraded to Underweight on elevated risks at Piper Sandler
07/20/22 Piper Sandler
DocuSign downgraded to Underweight from Neutral at Piper Sandler
07/13/22 Piper Sandler
DocuSign price target lowered to $65 from $75 at Piper Sandler
SAIA Saia
$219.34 /

-8.52 (-3.74%)

08/22/22 Evercore ISI
Saia downgraded to In Line from Outperform at Evercore ISI
07/28/22 Stifel
Saia price target lowered to $229 from $238 at Stifel
07/28/22 Susquehanna
Saia price target raised to $270 from $265 at Susquehanna
07/28/22 Deutsche Bank
Saia price target lowered to $300 from $377 at Deutsche Bank
LH Labcorp
$248.21 /

-1.13 (-0.45%)

08/22/22 Morgan Stanley
Labcorp assumed with an Overweight at Morgan Stanley
07/29/22 Mizuho
LabCorp price target lowered to $296 from $323 at Mizuho
05/04/22 Mizuho
LabCorp price target lowered to $323 from $354 at Mizuho
05/03/22 Deutsche Bank
LabCorp price target lowered to $265 from $294 at Deutsche Bank
DGX Quest Diagnostics
$135.11 /

-0.39 (-0.29%)

08/22/22 Morgan Stanley
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley
07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
WALD Waldencast Acquisition
$8.94 /

+ (+0.00%)

08/22/22 Raymond James
Waldencast Acquisition initiated with an Outperform at Raymond James
08/17/22 Jefferies
Waldencast Acquisition initiated with a Buy at Jefferies
07/19/22 Telsey Advisory
Waldencast Acquisition initiated with an Outperform at Telsey Advisory
PGPHF Partners Group
$991.35 /

-48.69 (-4.68%)

08/22/22 Credit Suisse
Partners Group initiated with an Outperform at Credit Suisse
07/20/22 Morgan Stanley
Partners Group price target lowered to CHF 1,168 at Morgan Stanley
07/18/22 JPMorgan
Partners Group price target lowered to CHF 1,500 from CHF 1,725 at JPMorgan
07/15/22 Barclays
Partners Group price target lowered to CHF 990 from CHF 1,040 at Barclays
CINC CinCor Pharma
$33.11 /

-0.21 (-0.63%)

08/21/22 Piper Sandler
CinCor Pharma initiated with an Overweight at Piper Sandler
08/08/22 Oppenheimer
CinCor Pharma price target raised to $60 from $35 at Oppenheimer
07/21/22 Oppenheimer
CinCor Pharma price target raised to $35 from $30 at Oppenheimer
02/01/22 Oppenheimer
CinCor Pharma initiated with an Outperform at Oppenheimer
VIPS Vipshop
$10.51 /

+0.53 (+5.31%)

UPS UPS
$205.65 /

-2.92 (-1.40%)

SNDR Schneider National
$24.69 /

-0.12 (-0.48%)

SAIA Saia
$219.34 /

-8.52 (-3.74%)

NFLX Netflix
$228.15 /

-13.26 (-5.49%)

LH Labcorp
$248.21 /

-1.13 (-0.45%)

KNX Knight-Swift
$54.50 /

-0.99 (-1.78%)

ELV Elevance Health
$508.26 /

+4.55 (+0.90%)

DOCU DocuSign
$63.80 /

-2.155 (-3.27%)

DGX Quest Diagnostics
$135.11 /

-0.39 (-0.29%)

DAO Youdao
$5.38 /

+0.24 (+4.67%)

COUP Coupa Software
$65.05 /

-2.72 (-4.01%)

CINC CinCor Pharma
$33.11 /

-0.21 (-0.63%)

BRKR Bruker
$59.78 /

+0.12 (+0.20%)

  • 11
    Aug
  • 07
    Jan
VIPS Vipshop
$10.51 /

+0.53 (+5.31%)

UPS UPS
$205.65 /

-2.92 (-1.40%)

NFLX Netflix
$228.15 /

-13.26 (-5.49%)

LH Labcorp
$248.21 /

-1.13 (-0.45%)

ELV Elevance Health
$508.26 /

+4.55 (+0.90%)

DOCU DocuSign
$63.80 /

-2.155 (-3.27%)

VIPS Vipshop
$10.51 /

+0.53 (+5.31%)

UPS UPS
$205.65 /

-2.92 (-1.40%)

SAIA Saia
$219.34 /

-8.52 (-3.74%)

NFLX Netflix
$228.15 /

-13.26 (-5.49%)

LH Labcorp
$248.21 /

-1.13 (-0.45%)

KNX Knight-Swift
$54.50 /

-0.99 (-1.78%)

ELV Elevance Health
$508.26 /

+4.55 (+0.90%)

DOCU DocuSign
$63.80 /

-2.155 (-3.27%)

DGX Quest Diagnostics
$135.11 /

-0.39 (-0.29%)

DAO Youdao
$5.38 /

+0.24 (+4.67%)

COUP Coupa Software
$65.05 /

-2.72 (-4.01%)

CINC CinCor Pharma
$33.11 /

-0.21 (-0.63%)

UPS UPS
$205.65 /

-2.92 (-1.40%)

NFLX Netflix
$228.15 /

-13.26 (-5.49%)

KNX Knight-Swift
$54.50 /

-0.99 (-1.78%)

ELV Elevance Health
$508.26 /

+4.55 (+0.90%)

DOCU DocuSign
$63.80 /

-2.155 (-3.27%)

COUP Coupa Software
$65.05 /

-2.72 (-4.01%)

CINC CinCor Pharma
$33.11 /

-0.21 (-0.63%)

Initiation
Quest Diagnostics assumed with an Equal Weight at Morgan Stanley » 07:48
08/22/22
08/22
07:48
08/22/22
07:48
DGX

Quest Diagnostics

$135.50 /

-0.4 (-0.29%)

Morgan Stanley analyst…

Morgan Stanley analyst Erin Wright assumed coverage of Quest Diagnostics with an Equal Weight rating and $142 price target. Quest's "subdued" base business growth in Q2 was largely anticipated, with the latest earnings upside primarily driven by strength in COVID PCR volumes, Wright tells investors in a research note. The analyst adds that clarity into its 2023 base growth has been limited, which may be understandable with the onboarding of a new CFO.

ShowHide Related Items >><<
DGX Quest Diagnostics
$135.50 /

-0.4 (-0.29%)

DGX Quest Diagnostics
$135.50 /

-0.4 (-0.29%)

07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
04/04/22 Citi
Quest Diagnostics downgraded on post-COVID uncertainty at Citi
DGX Quest Diagnostics
$135.50 /

-0.4 (-0.29%)

DGX Quest Diagnostics
$135.50 /

-0.4 (-0.29%)

Hot Stocks
Quest Diagnostics launches test panel to screen hepatitis C in early pregnancy » 07:33
08/17/22
08/17
07:33
08/17/22
07:33
DGX

Quest Diagnostics

$140.50 /

-0.59 (-0.42%)

Quest Diagnostics…

Quest Diagnostics launched a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people easily and reliably for hepatitis C with other laboratory tests typically ordered during early pregnancy. The company developed the new test panel to include HCV antibody testing with reflex to quantitative real-time PCR in response to findings from a Quest Diagnostics Health Trends study published in Obstetrics & Gynecology in June which found that less than 41% of pregnant people were screened for HCV in 2021. In recent years, hepatitis C infections have risen in pregnant people and other populations in the U.S., largely due to increased intravenous drug use.

ShowHide Related Items >><<
DGX Quest Diagnostics
$140.50 /

-0.59 (-0.42%)

DGX Quest Diagnostics
$140.50 /

-0.59 (-0.42%)

07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
04/04/22 Citi
Quest Diagnostics downgraded on post-COVID uncertainty at Citi
DGX Quest Diagnostics
$140.50 /

-0.59 (-0.42%)

DGX Quest Diagnostics
$140.50 /

-0.59 (-0.42%)

Conference/Events
Quest Diagnostics participates in a conference call with JPMorgan » 12:25
08/15/22
08/15
12:25
08/15/22
12:25
DGX

Quest Diagnostics

$141.14 /

+0.58 (+0.41%)

Life Science Tools &…

Life Science Tools & Diagnostics Analyst Vatnsdal holds a conference call with CEO Rusckowski and CEO-elect & EVP Davis on August 15 at 1 pm hosted by JPMorgan.

ShowHide Related Items >><<
DGX Quest Diagnostics
$141.14 /

+0.58 (+0.41%)

DGX Quest Diagnostics
$141.14 /

+0.58 (+0.41%)

07/22/22 Mizuho
Quest Diagnostics price target lowered to $160 from $185 at Mizuho
07/22/22 Credit Suisse
Quest Diagnostics price target lowered to $143 from $158 at Credit Suisse
04/24/22 UBS
Quest Diagnostics price target raised to $150 from $139 at UBS
04/04/22 Citi
Quest Diagnostics downgraded on post-COVID uncertainty at Citi
DGX Quest Diagnostics
$141.14 /

+0.58 (+0.41%)

DGX Quest Diagnostics
$141.14 /

+0.58 (+0.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.